Detail

Study ID: ECOG-ACRIN EA9161

Title:

A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Location:
Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region, Thief River Falls
Principal Investigator:
Preston Steen, MD,Preston Steen, MD,Preston Steen, MD,Preston Steen, MD
Disease:
CLL (Chronic Lymphocytic Leukemia)
Stage:
Phase III
Status:
Active - Open to Accrual